Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 195

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy

Open access
Galluzzi, Lorenzo, Vacchelli, Erika, Eggermont, Alexander, Fridman, Wolf Hervé, Galon, Jérôme, Sautès-Fridman, Catherine, Tartour, Eric, Zitvogel, Laurence, Kroemer, Guido·2012·OncoImmunology

Abstract

Toll-like receptors (TLRs) are prototypic pattern recognition receptors (PRRs) best known for their ability to activate the innate immune system in response to conserved microbial components such as lipopolysaccharide and double-stranded RNA. Accumulating evidence indicates that the function of TLRs is not restricted to the elicitation of innate immune responses against invading pathogens. TLRs have indeed been shown to participate in tissue repair and injury-induced regeneration as well as in adaptive immune responses against cancer. In particular, TLR4 signaling appears to be required for the efficient processing and cross-presentation of cell-associated tumor antigens by dendritic cells, which de facto underlie optimal therapeutic responses to some anticancer drugs. Thus, TLRs constitute prominent therapeutic targets for the activation/intensification of anticancer immune responses. In line with this notion, long-used preparations such as the Coley toxin (a mixture of killed Streptococcus pyogenes and Serratia marcescens bacteria) and the bacillus Calmette-Guérin (BCG, an attenuated strain of Mycobacterium bovis originally developed as a vaccine against tuberculosis), both of which have been associated with consistent anticancer responses, potently activate TLR2 and TLR4 signaling. Today, besides BCG, only one TLR agonist is FDA-approved for therapeutic use in cancer patients: imiquimod. In this Trial Watch, we will briefly present the role of TLRs in innate and cognate immunity and discuss the progress of clinical studies evaluating the safety and efficacy of experimental TLR agonists as immunostimulatory agents for oncological indications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4161/onci.20696

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 242

  1. 10.1016/0092-8674(85)90275-2 · DOI · Paper page
  2. 10.1016/0092-8674(88)90516-8 · DOI · Paper page
  3. 10.1016/S0092-8674(00)80172-5 · DOI · Paper page
  4. 10.1038/351355b0 · DOI · Paper page
  5. 10.1093/dnares/1.1.27 · DOI · Paper page
  6. 10.1006/geno.1996.0150 · DOI
  7. 10.1038/41131 · DOI · Paper page
  8. 10.1038/26239 · DOI · Paper page
  9. 10.1126/science.282.5396.2085 · DOI · Paper page
  10. 10.1126/science.270.5243.1804 · DOI · Paper page
  11. 10.1016/S1097-2765(00)80265-8 · DOI · Paper page
  12. 10.1073/pnas.0502272102 · DOI · Paper page
  13. 10.1126/science.1102218 · DOI · Paper page
  14. 10.1038/nrd3203 · DOI · Paper page
  15. 10.1016/S0167-4781(00)00289-X · DOI · Paper page
  16. 10.4049/jimmunol.0901888 · DOI · Paper page
  17. 10.4049/jimmunol.174.5.2942 · DOI · Paper page
  18. 10.1371/journal.pone.0012713 · DOI
  19. 10.1186/1742-2094-5-53 · DOI
  20. 10.1126/science.1094351 · DOI · Paper page
  21. 10.1126/science.1109893 · DOI · Paper page
  22. 10.1074/jbc.M110.171025 · DOI
  23. 10.1074/jbc.M110.159590 · DOI · Paper page
  24. 10.1038/35092578 · DOI · Paper page
  25. 10.1016/S1097-2765(00)80136-7 · DOI · Paper page
  26. 10.1038/nature01889 · DOI · Paper page
  27. 10.1126/science.1087262 · DOI · Paper page
  28. 10.1038/nature03464 · DOI · Paper page
  29. 10.1038/ni986 · DOI · Paper page
  30. 10.4049/jimmunol.1003093 · DOI
  31. 10.1002/eji.201040547 · DOI
  32. 10.1074/jbc.M200497200 · DOI · Paper page
  33. 10.4049/jimmunol.164.1.13 · DOI · Paper page
  34. 10.1097/PPO.0b013e3182325d4d · DOI
  35. 10.4049/jimmunol.174.8.5016 · DOI · Paper page
  36. 10.4049/jimmunol.168.12.5989 · DOI · Paper page
  37. 10.1038/nrc2541 · DOI · Paper page
  38. 10.4161/cc.8.23.10191 · DOI
  39. 10.1126/science.1208347 · DOI · Paper page
  40. 10.4161/cc.8.22.10026 · DOI · Paper page
  41. 10.4161/auto.19009 · DOI
  42. 10.4049/jimmunol.182.3.1449 · DOI · Paper page
  43. 10.4161/onci.1.2.19026 · DOI
  44. 10.1038/nrd3626 · DOI · Paper page
  45. 10.1111/j.1600-065X.2007.00573.x · DOI · Paper page
  46. 10.1189/jlb.0103026 · DOI · Paper page
  47. 10.1128/IAI.71.8.4238-4249.2003 · DOI
  48. 10.1158/0008-5472.CAN-03-1518 · DOI
  49. 10.1038/ni758 · DOI · Paper page
  50. 10.1126/science.1177319 · DOI · Paper page
  51. 10.1038/nrd1880 · DOI
  52. 10.1126/science.1138963 · DOI · Paper page
  53. 10.1056/NEJMp078053 · DOI · Paper page
  54. 10.4049/jimmunol.175.7.4641 · DOI · Paper page
  55. 10.1189/jlb.0807586 · DOI · Paper page
  56. 10.4049/jimmunol.165.7.3541 · DOI · Paper page
  57. 10.4049/jimmunol.165.5.2683 · DOI
  58. 10.1016/j.mimet.2007.11.016 · DOI
  59. 10.1111/j.1349-7006.2008.00832.x · DOI
  60. 10.1038/1911111a0 · doi:10.1038/1911111a0
  61. Mizuno D, 1968, Cancer Res, 28, 1531
  62. 10.1002/ijc.2910250317 · doi:10.1002/ijc.2910250317
  63. 10.1227/01.NEU.0000249280.61761.2E · DOI
  64. 10.1158/1078-0432.CCR-10-3262 · DOI
  65. 10.1038/348550a0 · DOI · Paper page
  66. Engelhardt R, 1991, Cancer Res, 51, 2524
  67. 10.1159/000163659 · DOI
  68. 10.1016/0959-8049(96)00186-4 · DOI
  69. 10.1111/j.1348-0421.1967.tb00350.x · DOI · Paper page
  70. 10.1097/01.cji.0000192106.32206.30 · DOI
  71. Hironaka K, 2006, Anticancer Res, 26, 3701
  72. 10.1016/0959-8049(93)90291-M · DOI
  73. 10.1016/S0002-9610(05)80068-6 · DOI
  74. 10.1023/A:1026428918301 · DOI
  75. 10.1046/j.1432-1327.2000.01370.x · doi:10.1046/j.1432-1327.2000.01370.x
  76. 10.4049/jimmunol.180.11.7574 · DOI
  77. 10.1016/j.intimp.2005.02.013 · doi:10.1016/j.intimp.2005.02.013
  78. 10.1016/j.ijrobp.2006.07.1381 · DOI
  79. 10.1371/journal.pone.0018833 · DOI
  80. 10.4049/jimmunol.172.6.3712 · DOI · Paper page
  81. 10.1517/13543784.16.7.935 · DOI
  82. 10.1126/science.1115253 · DOI · Paper page
  83. 10.1126/science.1155406 · DOI · Paper page
  84. 10.4049/jimmunol.176.8.4894 · DOI · Paper page
  85. 10.1158/0008-5472.CAN-09-1890 · DOI
  86. 10.1158/0008-5472.CAN-10-3490 · DOI
  87. 10.1073/pnas.64.1.67 · doi:10.1073/pnas.64.1.67
  88. 10.1016/j.vaccine.2008.10.024 · DOI
  89. 10.1089/jir.1986.6.373 · doi:10.1089/jir.1986.6.373
  90. 10.1097/00000421-198708000-00003 · doi:10.1097/00000421-198708000-00003
  91. Carter WA, 1985, J Biol Response Mod, 4, 613
  92. Carter WA, 1985, J Biol Response Mod, 4, 495
  93. Hubbell HR, 1987, J Biol Response Mod, 6, 525
  94. 10.2176/nmc.38.469 · doi:10.2176/nmc.38.469
  95. 10.1073/pnas.0605978104 · DOI · Paper page
  96. 10.1158/0008-5472.CAN-09-1162 · DOI
  97. Harrison SD, 1990, J Biol Response Mod, 9, 395
  98. 10.1073/pnas.1113099109 · DOI · Paper page
  99. 10.4161/cbt.10.12.13450 · DOI
  100. 10.1158/1078-0432.CCR-10-1140 · DOI
  101. Brodsky I, 1985, J Biol Response Mod, 4, 669
  102. 10.1093/infdis/132.4.434 · DOI · Paper page
  103. 10.1126/science.408923 · doi:10.1126/science.408923
  104. 10.1093/infdis/137.1.78 · doi:10.1093/infdis/137.1.78
  105. 10.1093/infdis/137.4.428 · doi:10.1093/infdis/137.4.428
  106. 10.1111/j.1348-0421.1982.tb00185.x · doi:10.1111/j.1348-0421.1982.tb00185.x
  107. Levine AS, 1978, Cancer Treat Rep, 62, 1907
  108. Lampkin BC, 1985, Cancer Res, 45, 5904
  109. 10.1023/A:1006458232384 · doi:10.1023/a:1006458232384
  110. Durie BG, 1985, J Biol Response Mod, 4, 518
  111. 10.1089/jir.1982.2.1 · DOI
  112. 10.1111/j.1749-6632.2009.04932.x · DOI
  113. 10.1007/s11060-008-9693-3 · DOI
  114. 10.1007/s11060-008-9705-3 · DOI
  115. 10.1093/neuonc/noq071 · doi:10.1093/neuonc/noq071
  116. 10.1158/1078-0432.CCR-09-3106 · DOI · Paper page
  117. Hawkins MJ, 1985, J Biol Response Mod, 4, 664
  118. 10.1016/0090-8258(86)90313-6 · doi:10.1016/0090-8258(86)90313-6
  119. Droller MJ, 1987, J Urol, 137, 202, 10.1016/S0022-5347(17)43953-X · doi:10.1016/s0022-5347(17)43953-x
  120. Krown SE, 1985, J Biol Response Mod, 4, 640
  121. Stevenson HC, 1985, J Biol Response Mod, 4, 650
  122. Ewel CH, 1992, Cancer Res, 52, 3005
  123. 10.1158/1078-0432.CCR-11-0891 · DOI
  124. 10.1586/erv.11.20 · DOI
  125. Panter G, 2009, Curr Opin Mol Ther, 11, 133
  126. 10.1126/science.157.3790.819 · doi:10.1126/science.157.3790.819
  127. 10.1093/intimm/dxm112 · DOI
  128. 10.4049/jimmunol.176.3.1363 · doi:10.4049/jimmunol.176.3.1363
  129. 10.1038/nature06765 · DOI · Paper page
  130. 10.1158/1078-0432.CCR-07-0274 · DOI · Paper page
  131. 10.1007/s00262-008-0459-8 · DOI
  132. 10.1158/0008-5472.CAN-05-0784 · DOI · Paper page
  133. 10.1016/S0140-6736(80)90057-4 · DOI
  134. 10.1023/A:1006498121628 · DOI
  135. 10.1016/0192-0561(90)90084-Z · doi:10.1016/0192-0561(90)90084-z
  136. 10.1093/annonc/mdm536 · DOI
  137. Lacour J, 1992, Eur J Surg Oncol, 18, 599
  138. Ducret JP, 1985, J Biol Response Mod, 4, 129
  139. 10.1089/jir.1996.16.631 · doi:10.1089/jir.1996.16.631
  140. 10.1038/nri3027 · DOI
  141. 10.1172/JCI36551 · DOI · Paper page
  142. 10.1126/science.1093620 · DOI · Paper page
  143. 10.1016/j.ymthe.2005.11.002 · DOI · Paper page
  144. 10.1158/0008-5472.CAN-10-3903 · DOI
  145. 10.1006/cimm.1999.1555 · DOI
  146. 10.1006/cimm.1998.1406 · DOI · Paper page
  147. 10.4049/jimmunol.175.3.1551 · DOI · Paper page
  148. 10.1006/cimm.2000.1673 · DOI
  149. 10.1006/cimm.2000.1689 · DOI
  150. 10.1016/j.vaccine.2009.07.062 · DOI
  151. 10.1086/513276 · DOI
  152. 10.1016/j.jhep.2007.02.025 · DOI · Paper page
  153. 10.1111/j.1365-2133.2008.08615.x · doi:10.1111/j.1365-2133.2008.08615.x
  154. 10.1186/1471-2172-8-26 · DOI
  155. 10.1089/jir.2007.0097 · DOI
  156. 10.4161/cbt.10.2.12163 · DOI
  157. 10.1158/1078-0432.CCR-07-1443 · DOI · Paper page
  158. 10.1177/0091270007303766 · DOI
  159. 10.1158/1078-0432.CCR-07-1938 · DOI
  160. 10.1007/s00262-010-0914-1 · DOI
  161. 10.1158/1078-0432.CCR-11-1625 · DOI · Paper page
  162. 10.1038/nrd2059 · DOI · Paper page
  163. 10.1038/sj.onc.1210911 · DOI · Paper page
  164. 10.1038/ni1280 · DOI · Paper page
  165. 10.1182/blood-2009-03-213363 · DOI
  166. Carpentier AF, 1999, Cancer Res, 59, 5429
  167. Carpentier AF, 2000, Clin Cancer Res, 6, 2469
  168. 10.1007/s00262-008-0586-2 · DOI
  169. 10.1002/ijc.21131 · DOI
  170. Paul S, 2003, Curr Opin Mol Ther, 5, 553
  171. 10.1007/s10875-004-6244-3 · DOI · Paper page
  172. 10.1016/j.vaccine.2004.01.058 · DOI · Paper page
  173. 10.1086/533467 · DOI
  174. 10.1158/1078-0432.CCR-07-0050 · DOI
  175. 10.1097/00002371-200411000-00006 · DOI · Paper page
  176. 10.1172/JCI23373 · doi:10.1172/jci23373 · Paper page
  177. 10.1158/1078-0432.CCR-07-4711 · DOI
  178. 10.3109/10428194.2011.608451 · DOI
  179. 10.1097/01.cji.0000211304.60126.8f · DOI
  180. 10.1158/1078-0432.CCR-07-0815 · DOI
  181. 10.1200/JCO.2010.28.9793 · DOI · Paper page
  182. 10.1016/j.jaad.2009.12.052 · DOI
  183. 10.1097/CJI.0b013e318174a4df · DOI
  184. 10.1200/JCO.2006.07.9129 · DOI · Paper page
  185. 10.1002/cncr.24473 · DOI
  186. 10.1097/CJI.0b013e31825481fe · DOI
  187. 10.1111/j.1349-7006.2010.01732.x · doi:10.1111/j.1349-7006.2010.01732.x
  188. 10.1200/JCO.2007.12.5807 · DOI · Paper page
  189. 10.1111/j.1349-7006.2009.01361.x · DOI
  190. 10.1200/JCO.2010.32.8971 · DOI
  191. 10.3816/CGC.2009.n.025 · DOI
  192. 10.1158/1078-0432.CCR-10-1811 · DOI
  193. 10.1517/13543784.7.9.1475 · DOI
  194. 10.1093/annonc/mdr030 · DOI
  195. 10.1215/S1522851705000475 · DOI · Paper page
  196. 10.1093/neuonc/nop047 · DOI · Paper page
  197. 10.1042/BST0351461 · DOI
  198. 10.1073/pnas.0501729102 · DOI
  199. Wang D, 2004, Int J Oncol, 24, 901
  200. 10.1158/1078-0432.CCR-09-1599 · DOI

200 of 242 shown

Cited by

See all 195

Metadata

Authors
Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G.
Venue
OncoImmunology
Published
2012-08
Volume
1
Issue
5
Pages
699-739
ISSN
  • 2162-4011 (ISSN-L)
  • 2162-402X
OpenAlex
W1977957999
Cited by
195
References
16
FWCI
12.82
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. https://app.cochat.ai/papers/10.4161/onci.20696
The paper
Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012). Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. OncoImmunology. https://doi.org/10.4161/onci.20696

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.